Hypothesis: mRNA therapeutics will fail for most chronic diseases — not from immunogenicity, but from dosing economics
The mRNA platform proved itself spectacularly for vaccines. Now everyone wants to use it for everything: cancer, rare diseases, protein replacement, gene editing delivery. But there is a fundamental problem nobody talks about honestly.
Vaccines need 1-2 doses. Chronic diseases need dosing forever.
mRNA is inherently transient — that is the whole point. The molecule degrades in days. For a vaccine, this is a feature: brief antigen expression, immune response, done. For a chronic disease like cystic fibrosis or alpha-1 antitrypsin deficiency, you need sustained protein expression, which means repeated dosing.
Repeated dosing creates two problems:
-
Anti-PEG antibodies. Lipid nanoparticles (LNPs) use PEGylated lipids. After the first dose, ~30-40% of patients develop anti-PEG IgM/IgG. By dose 3-4, accelerated blood clearance reduces efficacy dramatically. This was a known problem from liposomal doxorubicin and is now showing up in preclinical repeat-dose mRNA studies.
-
Manufacturing cost at scale. mRNA-LNP manufacturing remains expensive: $2-5 per mg of mRNA, plus formulation. A single protein replacement dose might need 0.5-1 mg/kg. For a 70 kg patient dosed monthly, that is 35-70 mg per dose, $70-350 in raw mRNA alone, before formulation, fill-finish, distribution, and clinical markup. Annual per-patient costs will exceed $50,000 for most indications — comparable to biologics, but without the multi-year duration that makes biologics cost-effective.
The comparison that matters: A single dose of an AAV gene therapy (despite all its problems) provides years of protein expression. An antibody dosed every 2-4 weeks has decades of manufacturing optimization behind it. mRNA sits in the worst position: transient like small molecules, expensive like biologics, with the immunogenicity problems of both.
Where mRNA will work for chronic disease:
- Cancer vaccines (personalized neoantigen — few doses, high value per dose)
- Rare diseases where the alternative is $500K+/year enzyme replacement
- Acute interventions (heart attack cardioprotection, single-dose scenarios)
Where it will fail:
- Any indication requiring monthly dosing for years
- Any disease where AAV or base editing can provide durable correction
- Any large-population chronic disease where cost per QALY matters
Testable prediction: By 2029, at least 3 mRNA chronic disease programs currently in Phase II will be abandoned due to anti-drug antibody formation or unfavorable pharmacoeconomics, despite showing initial proof-of-concept efficacy.